Listed

Paysign, Inc.: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on May 11, 2023 and accepted by EDGAR at May 11, 2023, 13:30 ET.

Share

Management's discussion and analysis

As filed, 24,126 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Forward-Looking Statements”). All statements other than statements of historical fact included in this report are Forward-Looking Statements. These Forward-Looking Statements are based on our current expectations, assumptions, estimates and projections about our business and our industry. Words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “propose,” “may,” and other similar expressions identify Forward-Looking statements. In the normal course of our business, we, in an effort to help keep our shareholders and the public informed about our operations, may from time-to-time issue certain statements, either in writing or orally, that contain, or may contain, Forward-Looking Statements. Although we believe that the expectations reflected in such Forward-Looking Statements are reasonable, we can give no assurance that such expectations will prove to have been correct. In addition, any statements that refer to expectations, projections, estimates, forecasts, or other characterizations of future events or circumstances are Forward-Looking Statements. These Forward-Looking Statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the Forward-Looking Statements. Such important factors (“Important Factors”) and other factors are disclosed in this report, including those factors discussed in “Part II - Item 1A. Risk Factors.” All prior and subsequent written and oral Forward-Looking Statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the Important Factors described below that could cause actual results to differ materially from our expectations as set forth in any Forward-Looking Statement made by or on behalf of us. You are cautioned not to place undue reliance on these Forward-Looking Statements, which relate only to events as of the date on which the statements are made. We undertake no obligation to publicly revise these Forward-Looking Statements to reflect events or circumstances that arise after the date hereof. You should refer to and carefully review the information in future documents we file with the Securities and Exchange Commission.

Overview

Paysign, Inc. (the “Company,” “Paysign,” “we” or “our”), headquartered in Nevada, was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. Paysign is a vertically integrated provider of prepaid card products and processing services for corporate, consumer and government applications. Our payment solutions are utilized by our corporate customers as a means to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. Public sector organizations can utilize our payment solutions to disburse public benefits or for internal payments. We market our prepaid card solutions under our Paysign® brand. As we are a payment processor and prepaid card program manager, we derive our revenue from all stages of the prepaid card lifecycle.

We provide a card processing platform consisting of proprietary systems and software applications based on the unique needs of our clients. We have extended our processing business capabilities through our proprietary Paysign platform. Through the Paysign platform, we provide a variety of services including transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service. The Paysign platform was built on modern cross-platform architecture and designed to be highly flexible, scalable and customizable. The platform’s flexibility and ease of customization has allowed us to expand our operational capabilities by facilitating our entry into new markets within the payments space. The Paysign platform delivers cost benefits and revenue building opportunities to our partners.

We have developed prepaid card programs for corporate incentive and rewards including, but not limited to, consumer rebates and rewards, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card. In 2022 we further expanded our product offerings to include prepaid payroll services and corporate disbursements. We also launched our first prepaid gift card product in a retail channel. In the future, we expect to further expand our product into other prepaid card offerings such as travel cards and expense reimbursement cards. Our cards are sponsored by or issuing bank partners.

Our revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income. Revenue from cardholder fees, interchange, card program management fees, and transaction claims processing fees is recorded when the performance obligation is fulfilled. Settlement income is recorded at the expiration of the card program.

We have two categories for our prepaid debit cards: (1) corporate and consumer reloadable cards, and (2) non-reloadable cards.

Reloadable Cards: These types of cards are generally classified as payroll or considered general purpose reloadable (“GPR”) cards. Payroll cards are issued by an employer to an employee in order to allow the employee to access payroll amounts that are deposited into an account linked to their card. GPR cards can also be issued to a consumer at a retail location or mailed to a consumer after completing an on-line application. GPR cards can be reloaded multiple times with a consumer’s payroll, government benefit, a federal or state tax refund or through cash reload networks located at retail locations. Reloadable cards are generally open-loop cards as described below.

Non-Reloadable Cards: These are generally one-time use cards that are only active until the funds initially loaded to the card are spent. These types of cards are generally used as gift or incentive cards. Normally these types of cards are used for the purchase of goods or services at retail locations and cannot be used to receive cash.

Both reloadable and non-reloadable cards may be open-loop, closed-loop, or restricted-loop. Open-loop cards can be used to receive cash at ATM locations by PIN; or purchase goods or services by PIN or signature at retail locations virtually anywhere that the network brand (American Express, Discover, Mastercard, Visa, etc.) is accepted. Closed-loop cards can only be used at a specific merchant. Restricted-loop cards can be used at several merchants, or a defined group of merchants, such as all merchants at a specific shopping mall.

The prepaid card market in the U.S. has experienced significant growth in recent years due to consumers and merchants embracing improved technology, greater convenience, more product choices and greater flexibility. Prepaid cards have also proven to be an attractive alternative to traditional bank accounts for certain segments of the population, particularly those without, or who could not qualify for, a checking or savings account.

We manage all aspects of the prepaid card lifecycle, from managing the card design and approval processes with partners and networks, to production, packaging, distribution, and personalization. We also oversee inventory and security controls, renewals, lost and stolen card management, and replacement. We deploy a fully staffed, in-house customer service department which utilizes bilingual customer service representatives, Interactive Voice Response, and two-way short message service messaging and text alerts.

Currently, we are focusing our marketing efforts on corporate incentive and expense prepaid card products in various market verticals including but not limited to general corporate expense, healthcare related markets including copay assistance, clinical trials and donor compensation, loyalty rewards, and incentive cards.

As part of our continuing platform expansion process, we evaluate current and emerging technologies for applicability to our existing and future software platform. To this end, we engage with various hardware and software vendors in evaluation of various infrastructure components. Where appropriate, we use third-party technology components in the development of our software applications and service offerings. Third-party software may be used for highly specialized business functions, which we may not be able to develop internally within time and budget constraints. Our principal target markets for processing services include prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico.

We have devoted more extensive resources to sales and marketing activities as we have added essential personnel to our marketing, sales and support teams. We market our Paysign payment solutions through direct marketing by the Company’s sales team. Our primary market focus is on companies that require a streamlined payment solution for rewards, rebates, payment assistance, and other payments to their customers, employees, agents and others. To reach these markets, we focus our sales efforts on direct contact with our target market and attendance at various industry specific conferences. We may, at times, utilize independent contractors who make direct sales and are paid commissions and/or restricted stock awards. We market our Paysign Premier product through existing communication channels to a targeted segment of our existing cardholders, as well as to a broad group of individuals, ranging from non-banked to fully banked consumers with a focus on long term users of our product.

In 2023, we plan to continue to invest additional funds in technology improvements, sales and marketing, customer service, and regulatory compliance. From time to time, we evaluate raising capital to enable us to diversify into new market verticals. If we do not raise new capital, we believe that we will still be able to expand into new vertical markets using internally generated funds.

Results of Operations

Three Months Ended March 31, 2023 and 2022

The following table summarizes our consolidated financial results:

Revenues Three Months Ended March 31, (Unaudited) 2023 2022 Variance $%
Plasma industry $9,360,067 $7,394,364 $1,965,703 26.6%
Pharma industry 589,562 806,568 (217,006) (26.9%)
Other 193,661 19,707 173,954 882.7%
Total revenues 10,143,290 8,220,639 1,922,651 23.4%
Cost of revenues 5,095,621 3,222,390 1,873,231 58.1%
Gross profit 5,047,669 4,998,249 49,420 1.0%
Gross margin % 49.8% 60.8%
Operating expenses
Selling, general and administrative 4,945,450 4,640,912 304,538 6.6%
Depreciation and amortization 845,016 679,171 165,845 24.4%
Total operating expenses 5,790,466 5,320,083 470,383 8.8%
Loss from operations $(742,797) $(321,834) $(420,963) 130.8%
Net loss $(160,130) $(309,395) $149,265 (48.2%)
Net margin % (1.6%) (3.8%)

18

The increase in total revenues of $1,922,651 for the three months ended March 31, 2023 compared to the same period in the prior year consisted primarily of a $1,965,703 increase in Plasma revenue, a $217,006 decrease in Pharma revenue, and a $173,954 increase in Other revenue. The increase in Plasma revenue was primarily due to an increase in the number of plasma centers and donations, and, consequently, dollars loaded to cards, cardholder fees, and interchange, as there continues to be an increase in demand for plasma driven by global increases of plasma protein therapies. The decrease in Pharma revenue was primarily due to the end of our Pharma prepaid programs in 2022, offset by the launch of new Pharma copay programs. The increase in Other revenue was primarily due to the launch of new payroll and retail programs.

Cost of revenues for the three months ended March 31, 2023 increased $1,873,231 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, and sales and commission expense. Cost of revenues increased during the first quarter of 2023 primarily due to an increase in cardholder usage activity, an increase in plastics, collateral and postage related to increase in the number of unique card loads, an increase in network expenses related to our Pharma copay business, a new direct network connection with Mastercard, and an increase in customer service expenses associated with the overall growth in our business, offset by a decline in sales commissions related to the restructuring of an agreement in the first quarter of 2022.

Gross profit for the three months ended March 31, 2023 increased $49,420 compared to the same period in the prior year resulting from the increase in Plasma revenue, the restructuring of an agreement mentioned above, and the beneficial impact of a variable cost structure as many of the Plasma transaction costs are variable in nature which are provided by third parties who charge us based on the number of active cards outstanding and the number of transactions that occurred during the period. The increase in gross profit was offset by an increase in network expenses related to our Pharma copay business, price increases by many of our third party service providers, a new direct network connection with Mastercard, and an increase in customer service expenses relating to the overall growth of our business. The decrease in gross margin resulted from the aforementioned factors.

Selling, general and administrative expenses (“SG&A”) for the three months ended March 31, 2023 increased $304,538 or 6.6% compared to the same period in the prior year and consisted primarily of an increase in compensation and benefits of approximately $1,180,000 due to continued hiring to support the Company’s growth, a tight labor market and increased personnel insurance costs. This increase was offset by an increase in capitalized platform development costs of approximately $810,000 and a decrease in outside professional services of approximately $120,000.

Depreciation and amortization expense for the three months ended March 31, 2023 increased $165,845 compared to the same period in the prior year. The increase in depreciation and amortization expense was primarily due to continued capitalization of new software and equipment, and continued enhancements to our platform.

For the three months ended March 31, 2023, we recorded a loss from operations of $742,797 representing a decline of $420,963 compared to the same period last year related to the aforementioned factors.

Other income for the three months ended March 31, 2023, increased $569,861 primarily related to an increase in interest rates and the associated interest income received on higher bank account balances at our sponsor bank.

We recorded an income tax expense of $1,530 for the three months ended March 31, 2023, which equates to an effective tax rate of (1.0%) primarily as a result of state taxes, a pretax loss and full valuation on our deferred tax asset. We recorded an income tax expense of $1,897 for the three months ended March 31, 2022, which equates to an effective tax rate of (0.6%) percent primarily as a result of the full valuation on our deferred tax asset in both the current and prior period and the tax benefit related to our stock-based compensation and a pretax loss in the prior period.

The net loss for the three months ended March 31, 2023 was $160,130, an improvement of $149,265 compared to the net loss of $309,395 for the three months ended March 31, 2022. The overall change in net loss relates to the aforementioned factors.

Key Performance Indicators and Non-GAAP Measures

Management reviews a number of metrics to help us monitor the performance of and identify trends affecting our business. We believe the following measures are the primary indicators of our quarterly and annual revenues:

Gross Dollar Volume Loaded on Cards – Represents the total dollar volume of funds loaded to all of our prepaid card programs. Our gross dollar volume loaded on cards was $379 million and $324 million for the three months ended March 31, 2023 and 2022, respectively. We use this metric to analyze the total amount of money moving into our prepaid card programs.

Conversion Rates on Gross Dollar Volume Loaded on Cards – Equals revenues, gross profit or net income conversion rates of gross dollar volume loaded on cards which are calculated by taking our total revenues, gross profit or net income (loss), respectively, as a numerator and dividing by the gross dollar volume loaded on cards as a denominator. As we derive a number of our financial results from cardholder fees, we utilize these metrics as an indication of the amount of money that is added to cards and will eventually be converted to revenues, gross profit and net income. Our total revenue conversion rates for the three months ended March 31, 2023 and 2022 were 2.68% or 268 basis points (“bps”), and 2.54% or 254 bps, respectively, of gross dollar volume loaded on cards. Our total gross profit conversion rates for the three months ended March 31, 2023 and 2022 were 1.33% or 133 bps, and 1.54% or 154 bps, respectively, of gross dollar volume loaded on cards. Our net loss conversion rates for the three months ended March 31, 2023 and 2022 were (0.04)% or (4) bps, and (0.10)% or (10) bps, respectively, of gross dollar volume loaded on cards.

Management also reviews key performance indicators, such as revenues, gross profit, operational expenses as a percent of revenues, and cardholder participation. In addition, we consider certain non-GAAP (or "adjusted") measures to be useful to management and investors evaluating our operating performance for the periods presented, and provide a financial tool for evaluating our ongoing operations, liquidity and management of assets. This information can assist investors in assessing our financial performance and measures our ability to generate capital for deployment and investment in new card programs. These adjusted metrics are consistent with how management views our business and are used to make financial, operating and planning decisions. These metrics, however, are not measures of financial performance under GAAP and should not be considered a substitute for revenue, operating income, net income (loss), earnings (loss) per share (basic and diluted) or net cash from operating activities as determined in accordance with GAAP. We consider the following non-GAAP measures, which may not be comparable to similarly titled measures reported by other companies, to be key performance indicators:

“EBITDA” is defined as earnings before interest, income taxes, and depreciation and amortization expense and "Adjusted EBITDA" reflects the adjustment to EBITDA to exclude stock-based compensation expense. A reconciliation of net loss to Adjusted EBITDA is provided in the table below.

Reconciliation of Adjusted EBITDA to net loss: Three Months Ended March 31, 2023 2022
Net loss $(160,130) $(309,395)
Income tax provision 1,530 1,897
Interest income, net (584,197) (14,336)
Depreciation and amortization 845,016 679,171
EBITDA 102,219 357,337
Stock-based compensation 618,244 569,502
Adjusted EBITDA $720,463 $926,839

20

Liquidity and Capital Resources

The following table sets forth the major sources and uses of cash:

Three Months Ended March 31, (Unaudited) 2023 2022
Net cash provided by operating activities $3,230,605 $5,137,144
Net cash used in investing activities (1,657,896) (674,860)
Net cash used in financing activities (666,018) –
Net increase in cash and restricted cash $906,691 $4,462,284

Comparison of Three months Ended March 31, 2023 and 2022

During the three months ended March 31, 2023 and 2022, we financed our operations through internally generated funds.

Cash provided by operating activities decreased $1,906,539 for the three months ended March 31, 2023, as compared to the same period in the prior year. The decrease in cash flow is primarily due to increases in accounts receivable of $4,475,101 and increased prepaid expenses and other current assets of $500,009 related to the purchase of inventory, software licenses and insurance. This was offset by increased customer card funding of $821,300 related to growth in our existing businesses and launch of new Pharma programs, increased amount of depreciation and amortization of $165,845 primarily related to ongoing investments in our technology platform and increases in accounts payable and accrued liabilities of $2,019,056. The changes in accounts receivable and accounts payable are primarily related to the growth in our Pharma copay business as we are invoiced by third party service providers at the end of the period and are due monies from our Pharma copay customers to cover these amounts due.

Cash used in investing activities increased $983,036 for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. The change between periods was primarily attributed to an increase in the capitalization of internally developed software as we continue to invest in our technology platform.

Cash used in financing activities increased $666,018 for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022. The change between periods was attributed to the repurchase of 200,000 shares of the company’s common stock at a price of $3.33 per share.

Our significant contractual cash requirements also include ongoing payments for lease liabilities. For additional information regarding our cash commitments and contractual obligations, see "Note 4 – LEASE” in the notes to the accompanying consolidated financial statements.

Sources of Liquidity

We believe that our available cash on hand, excluding restricted cash, at March 31, 2023 of $6,399,860, along with our forecast for revenues and cash flows for the remainder of the year and for 2024, will be sufficient to sustain our operations for the next eighteen months. In light of the recent bank failures, we continue to monitor the health and soundness of our bank relationships through publicly available information. Based on recent SEC filings, we have not discovered any issues that would cause us to alter our relationships.

Critical Accounting Policies and Estimates

Our significant accounting policies are described in Note 1 of the Notes to Consolidated Financial Statements and our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Our estimates are based on our experience and our interpretation of economic, political, regulatory, and other factors that affect our business prospects. Actual results may differ significantly from our estimates.

Controls and procedures

As filed, 1,466 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures.

Disclosure controls and procedures means controls and other procedures that are designed to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and to ensure that information required to be disclosed by us in those reports is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2023. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of March 31, 2023, the end of the period covered by this Quarterly Report on Form 10-Q.

Changes in Internal Control over Financial Reporting

During the quarter ended March 31, 2023, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-01-01 to 2023-03-31$10.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-01-01 to 2023-03-31$5.1mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-01-01 to 2023-03-31$5.0mus-gaap:GrossProfit
Selling, general and administrative3 months2023-01-01 to 2023-03-31$4.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-01-01 to 2023-03-31−$742.8kus-gaap:OperatingIncomeLoss
Income tax3 months2023-01-01 to 2023-03-31$1.5kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-01-01 to 2023-03-31−$160.1kus-gaap:NetIncomeLoss
Diluted EPS3 months2023-01-01 to 2023-03-31$0.00us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-01-01 to 2023-03-31$0.00us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-01-01 to 2023-03-3152,403,454 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-01-01 to 2023-03-31$3.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-01-01 to 2023-03-31$44.9kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2023-01-01 to 2023-03-31$666.0kus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2023-03-31$6.4mus-gaap:Cash
Current assetsAt period end2023-03-31$104.1mus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$115.4mus-gaap:Assets
Current liabilitiesAt period end2023-03-31$96.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-03-31$99.3mus-gaap:Liabilities
Shareholders' equityAt period end2023-03-31$16.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-23-003174. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.